BYSI - BeyondSpring Inc logo

BeyondSpring Inc

BYSI
Net income grew 100% of years5Y
Compare BYSI Hold

BeyondSpring Inc. develops biopharmaceutical therapies focused on oncology, particularly its lead asset Plinabulin for non-small cell lung cancer and chemotherapy-induced neutropenia. The company also explores combinations with immuno-oncology agents.

⚕️ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago →$28today

Score Overview

1 Year
Score—
Net Growth16.35%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score6.1
Net Growth89.58%
Net TrendEvery year
Net Income Consistency—
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency—
All Time
Score—
Net Growth92.71%
Net Trend78%
Net Income Consistency
Rev Growth—
Rev Trend33%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where BeyondSpring Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. BYSI does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 0.45—
1 Year2025-10-22
$ 2.04-78.18%
5 Years2021-10-22
$ 15.99-97.22%
All Time2017-03-09
$ 16.80-97.35%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 6M$ 6M
2025$ 0.00-$ 7M$ 12M
2024$ 0.00-$ 11M$ 2M
2023$ 1M-$ 21M$ 15M
2022$ 1M-$ 33M$ 37M
2021$ 1M-$ 64M$ 72M
2020$ 180K-$ 60M$ 109M
2019$ 0.00-$ 38M$ 35M
2018$ 0.00-$ 54M$ 3M
IPO2017$ 0.00-$ 91M$ 30M
BYSI - BeyondSpring Inc logo

BeyondSpring Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 180K to $ 0.00 and net income went from -$ 60M to -$ 7M. Revenue increased in 1 of those 5 years; net income in every one.

BeyondSpring Inc currently holds a 5-year HDB Score of 6.1 out of 10. How the HDB Score is calculated.

Membership

Explore BYSI with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies